PharmTech Drug Digest 11.20
|Articles|February 27, 2015

Advanced Aseptic Liquid Processing Technology

Weiler Engineering, Inc.’s corporate focus is to provide advanced aseptic liquid processing technology through the application of customized ASEP-TECH® Blow/Fill/Seal machinery and services. Serving the pharmaceutical industry has been Weiler’s core business for more than 50 years. Weiler focuses on the patient and strives to provide the safest sterile aseptic packaging process for pharmaceutical liquids. This concept is based on studying and implementing learned technological advances driven by Science.

Weiler Engineering, Inc.’s corporate focus is to provide advanced aseptic liquid processing technology through the application of customized ASEP-TECH® Blow/Fill/Seal machinery and services. Serving the pharmaceutical industry has been Weiler’s core business for more than 50 years. Weiler focuses on the patient and strives to provide the safest sterile aseptic packaging process for pharmaceutical liquids. This concept is based on studying and implementing learned technological advances driven by Science.  

Weiler Engineering, Inc.’s, ASEP-TECH® Blow/Fill/Seal machines are manufactured in Elgin, IL USA with 85% of production exported to more than 35 companies around the world.

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.